1. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy;Nabholtz;J. Clin. Oncol.,1999
2. Sjöström J, Mouridsen H, Pluzanska A, et al. Taxotere versus methotrexate–5-fluorouracil in patients with advanced anthracycline-resistant breast cancer: preliminary results of a randomized phase III study by Scandinavian Breast Cancer Group. Proc ASCO 1998, abstract 427.
3. Bonneterre J, Roche H, Monnier A, et al. Docetaxel versus 5 fluorouracil–vinorelbine in patients with metastatic breast cancer as second line chemotherapy: a phase III study. Proc 21st Annual San Antonio Breast Cancer Symposium 1998, abstract 223.
4. A multicentre phase II study of docetaxel 75 mg/m2 as first-line chemotherapy for patients with advanced breast cancer;Diéras;Br. J. Cancer,1996
5. Docetaxel in combination chemotherapy for metastatic breast cancer;Khayat;Semin. Oncol.,1997